Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials

To our knowledge, the MMAI model is the first validated predictive biomarker to guide ADT duration with RT in localized/locally advanced PCa. Approximately one third of men with high-risk PCa could safely be spared the additional 24 months of ADT and the associated morbidity.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-04-16
DOI
https://doi.org/10.1200/jco.24.00365
Citations
15
Primary Topic
Prostate Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
22.78
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials

Joseph P. Rodgers, Jacqueline Griffin, Osama Mohamad, Paul Linh Nguyen et al.
15 citations
Journal of Clinical Oncology
Prostate Cancer Diagnosis and Treatment
22.78
article

Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials

Joseph P. Rodgers, Jacqueline Griffin, Osama Mohamad, Paul Linh Nguyen, Felix Yi-Chung Feng, Todd Matthew Morgan, Jeffry Simko, Ali El‐Gayed, Andrew J. Armstrong, Emmalyn Chen, Howard M. Sandler, Rikiya Yamashita, Elizabeth Gore, Rana R. McKay, Steve P. Lee, Jedidiah M. Monson, Andre Esteva, Phuoc T. Tran, Oliver A. Sartor, Daniel Eidelberg Spratt, Mark E. Augspurger, Vinnie Y.T. Liu, Huei–Chung Huang, Christopher A. Peters, Sandy DeVries, John H. Carson, Ramprasaath R. Selvaraju
article en
15 citations

Abstract

To our knowledge, the MMAI model is the first validated predictive biomarker to guide ADT duration with RT in localized/locally advanced PCa. Approximately one third of men with high-risk PCa could safely be spared the additional 24 months of ADT and the associated morbidity.

Journal of Clinical OncologyVol. 43(32)
American College of Radiology (US), University of Maryland, Baltimore (US), Cedars-Sinai Medical Center (US), Brigham and Women's Hospital (US), University of California, San Francisco (US), Clarkson College (US), Medical College of Wisconsin (US), University of Michigan (US), University of California San Diego (US), Community Health Systems - Regional Hospital of Scranton (US), Saint Agnes Medical Center (US), Milwaukee VA Medical Center (US), Mayo Clinic in Arizona (US), Duke Medical Center (US), Baptist Medical Center Jacksonville (US), VA Long Beach Healthcare System (US), Northeast Radiation Oncology Center (US), NRG Oncology (US), Artistic Realization Technologies (US), Case Western Reserve University (US)
Good health and well-being
Openalex Percentile: Top 0%
Prostate Cancer Diagnosis and Treatment
22.78
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.